Skip to main content

Methicillin-resistant Staphylococcus aureus bacteremia at a university hospital in Japan


Methicillin-resistant Staphylococcus aureus (MRSA) has become a leading cause of infections in hospitals, and mortality from MRSA bacteremia is high. In this study, we assessed the clinical characteristics and optimum management of 115 patients with MRSA bacteremia who were admitted to Osaka University Hospital between January 2006 and December 2010. Sixty-nine of the patients survived and 46 died of heart failure or renal failure. The nonsurvivors had reduced levels of platelets and albumin, and increased aspartate aminotransferase, total bilirubin, blood urea nitrogen, and creatinine levels. Other causes of death included sepsis, septic shock plus respiratory failure, disseminated intravascular coagulation, and unknown causes. However, a significant number of those whose infections were catheter-derived survived. Nonsurvivors were more often administered catecholamines and consultation with an infection-control team (ICT) was significantly associated with improved survival. Patients about whom the ICT were consulted were administered significantly more additional anti-MRSA drugs, for example trimethoprim–sulfamethoxazole, clindamycin, and gentamycin, than patients who were not the subject of consultation, although trough values for vancomycin did not differ between the two groups. Catheter removal was significantly higher for surviving patients with severe or complicated infections. These results suggest the status of patients with MRSA bacteremia who did not survive was worse than those who did survive, but that ICT consultation might significantly affect survival by recommendation of appropriate care and anti-MRSA drug use.

This is a preview of subscription content, access via your institution.


  1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92.

    PubMed  Article  Google Scholar 

  2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.

    PubMed  Article  Google Scholar 

  3. Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, European Antimicrobial Resistance Surveillance System Participants, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.

    PubMed  Article  Google Scholar 

  4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9.

    PubMed  Article  Google Scholar 

  5. Gould IM. MRSA bacteraemia. Int J Antimicrob Agents. 2007;30:S66–70.

    PubMed  Article  CAS  Google Scholar 

  6. Gómez J, García-Vázquez E, Baños R, Canteras M, Ruiz J, Baños V, et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis. 2007;26:239–45.

    PubMed  Article  Google Scholar 

  7. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis. 2008;198:336–43.

    PubMed  Article  Google Scholar 

  8. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379–86.

    PubMed  Article  CAS  Google Scholar 

  9. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17–60.

    PubMed  Article  Google Scholar 

  10. Takakura S, Fujihara N, Saito T, Kimoto T, Ito Y, Iinuma Y, et al. Improved clinical outcome of patients with Candida bloodstream infections through direct consultation by infectious diseases physicians in a Japanese university hospital. Infect Control Hosp Epidemiol. 2006;27:964–8.

    PubMed  Article  Google Scholar 

  11. The Committee for the Japanese Respiratory Society guidelines for the management of respiratory infections. The Japanese Respiratory Society guidelines for the management of hospital-acquired pneumonia in adults. Respirology. 2009;14:S1–71.

    Google Scholar 

  12. Silvestre J, Póvoa P, Coelho L, Almeida E, Moreira P, Fernandes A, et al. Is C-reactive protein a good prognostic marker in septic patients? Intensive Care Med. 2009;35:909–13.

    PubMed  Article  CAS  Google Scholar 

  13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138–44.

    PubMed  Article  Google Scholar 

  14. Walker TM, Bowler IC, Bejon P. Risk factors for recurrence after Staphylococcus aureus bacteraemia. A retrospective matched case–control study. J Infect. 2009;58:411–6.

    PubMed  Article  Google Scholar 

  15. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45.

    PubMed  Article  CAS  Google Scholar 

  16. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim–sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390–8.

    PubMed  CAS  Google Scholar 

  17. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother. 2007;60:788–94.

    PubMed  Article  CAS  Google Scholar 

  18. Gould IM. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents. 2008;31(Suppl 2):1–9.

    PubMed  Article  CAS  Google Scholar 

  19. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536–42.

    PubMed  Article  CAS  Google Scholar 

Download references


The authors thank Yoshimasa Wagatsuma (SUNMEDIA, Tokyo, Japan) for support with the statistical analysis and Forte Inc. (Tokyo, Japan) for proofreading the manuscript.

Conflict of interest


Author information

Authors and Affiliations


Corresponding author

Correspondence to Masafumi Seki.

Additional information

M. Isobe and M. Seki contributed equally to this work.

About this article

Cite this article

Isobe, M., Uejima, E., Seki, M. et al. Methicillin-resistant Staphylococcus aureus bacteremia at a university hospital in Japan. J Infect Chemother 18, 841–847 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Infection-control team
  • Consultation
  • Sepsis
  • Anti-MRSA drugs
  • Catheter